TP53 and acute lymphoblastic leukemia: We also confirmed the robust synergistic interaction of adavosertib with clofarabine, an alternative nucleoside analog used in the relapsed ALL treatment setting (Additional file 1: Fig. S6A), achieving Synergyarea scores of 17.3 ± 7.8 and 11.2 ± 0.4 in the TP53+/+ and TP53−/− lines respectively (Additional file 1: Fig. S6B).